NLM Logo

Clinical Trials, Phase II as Topic MeSH Descriptor Data 2023


MeSH Heading
Clinical Trials, Phase II as Topic
Tree Number(s)
E05.318.372.250.250.210
N05.715.360.330.250.250.210
N06.850.520.450.250.250.210
Unique ID
D017322
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D017322
Annotation
for general design, methodology, economics, etc. of phase II clinical trials; a different heading CLINICAL TRIAL, PHASE II is used for reports of a specific phase II clinical trial
Scope Note
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Entry Term(s)
Drug Evaluation, FDA Phase 2 as Topic
Drug Evaluation, FDA Phase II as Topic
Evaluation Studies, FDA Phase 2 as Topic
Evaluation Studies, FDA Phase II as Topic
Previous Indexing
Clinical Trials (1980-1992)
Drug Evaluation (1980-1992)
Public MeSH Note
2008; see CLINICAL TRIALS, PHASE II 1993-2007; for DRUG EVALUATION, FDA PHASE II see DRUG EVALUATION 1980-1992; for EVALUATION STUDIES, FDA PHASE II see DRUG EVALUATION 1982-1992
History Note
2008(1993)
Date Established
1993/01/01
Date of Entry
1992/05/13
Revision Date
2018/06/29
Clinical Trials, Phase II as Topic Preferred
Evaluation Studies, FDA Phase II as Topic Narrower
Drug Evaluation, FDA Phase II as Topic Narrower
page delivered in 0.166s